Samjin Pharmaceutical-Simplex Sign Joint Research Agreement on AI Drug Development

Lee Soo-min, Head of Samjin Pharmaceutical Research Center (left), and Cho Sung-jin, CEO of Simplex, are posing for a commemorative photo after signing a joint research agreement.

[Asia Economy Reporter Lee Gwanju] Samjin Pharmaceutical announced on the 24th that it has signed an agreement with Simplex, a domestic artificial intelligence (AI) new drug development company, for joint research on AI new drug development.

Through this agreement, Samjin Pharmaceutical will propose multiple drug targets currently under review to Simplex, and Simplex plans to sequentially secure promising candidate substances by applying 'CEEK-CURE,' a new drug candidate discovery platform based on 'Explainable AI' technology.

The candidate substances discovered by Simplex will be verified by Samjin Pharmaceutical, which will also carry out the necessary procedures for commercialization. The intellectual property rights for the derived new drug candidates will be jointly owned by both companies, while the exclusive license required for commercialization will be held solely by Samjin Pharmaceutical.

Lee Sumin, Head of Research Center at Samjin Pharmaceutical, said, “We expect to significantly reduce the time and cost required for new drug development through joint research utilizing AI technology with Simplex,” and added, “We plan to actively pursue joint research with leading domestic and international research institutions and companies through an open innovation strategy.”

Cho Sungjin, CEO of Simplex, stated, “We are honored to form a partnership with Samjin Pharmaceutical, which is strengthening its new drug pipeline through this joint research,” and added, “We will focus on enabling the rapid discovery of new candidate substances through Simplex’s AI-based platform.”

This content was produced with the assistance of AI translation services.